US6068857A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Microparticles containing active ingredients, agents containing these microparticles, their use for ultrasound-controlled release of active ingredients, as well as a process for their production
Assignee: Acusphere Inc
•
Filing: 1994-08-25
•
Granted: 2000-05-30
•
Expires: 2014-08-25
Abstract
Abstract The invention relates to new microparticles containing active ingredients, which contain at least one gas or a gaseous phase in addition to the active ingredient(s), agents containing these particles (microparticulate systems), their use for ultrasound-controlled in vivo release of active ingredients, as well as a process for the production of particles and agents.
Inventors
- 👤 Werner Weitschies
- 👤 Dieter Heldmann
- 👤 Peter Hauff
- 👤 Thomas Fritzsch
- 👤 Harald Stahl
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:32
CPC Classifications
A; A61; A61K; A61K41/00; A61K41/0028; A61K9/00; A61K9/14; A61K9/16; A61K49/00; A61K49/22; A61K49/222; A61K49/223; A61K9/0002; A61K9/0009; A61K9/1605; A61K9/1629; A61K9/1635; A61K9/1641; A61K9/1647; A61K9/48; A61K9/50; Y; Y10; Y10S; Y10S977/00; Y10S977/70; Y10S977/773; Y10S977/902; Y10S977/904; Y10S977/915; Y10S977/927; Y10S977/929
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
80 words
A microparticle solution comprising microparticles having a biodegradeable polymer shell and, incorporated within the shell, at least one pharmaceutically active ingredient releasable in vivo by application of ultrasound waves and a gaseous phase and having no pharmaceutically active ingredient in the solution other than within the microparticles, wherein the microparticle solution are prepared by treating in an autoclave microparticles comprising the biocompatible shell and gaseous phase with a solution of the at least one active ingredient in a supercritical gas.
Claim 2
Dependent Claim
80 words
A microparticle solution comprising microparticles having a biodegradeable polymer shell and, incorporated within the shell, at least one pharmaceutically active ingredient releasable in vivo by application of ultrasound waves and a gaseous phase and having no pharmaceutically active ingredient in the solution other than within the microparticles, wherein the microparticle solution are prepared by treating in an autoclave microparticles comprising the biocompatible shell and gaseous phase with a solution of the at least one active ingredient in a supercritical gas.
Claim 3
Dependent Claim
23 words
The microparticle solution of claim 1, wherein the supercritical gas is supercritical carbon dioxide, supercritical nitrogen, supercritical ammonia or a supercritical noble gas.
Claim 4
Dependent Claim
20 words
The microparticle solution of claim 1, wherein the density of the microparticle solution is less than 0.8 g/cm 3 .
Claim 5
Dependent Claim
18 words
The microparticle solution of claim 1, wherein the particle size of the microparticle solution is 0. 1-10 μm.
Claim 6
Dependent Claim
59 words
The microparticle solution of claim 1, wherein the biodegradeable polymer shell is comprised of proteins, gelatin, fibrinogen, collagen, crosslinked polypeptides, reaction products of proteins with polyethylene glycol, starch, chitin, chitosan, pectin, polylactic acid, copolymers consisting of lactic acid and glycolic acid, polycyanoacrylates, polyesters, polyamides, polycarbonates, polyphosphazenes, polyamnino acids, poly-ξ-caprolactone, copolymers consisting of lactic acid and ξ-caprolactone or combinations thereof.
Claim 7
Dependent Claim
45 words
The microparticle solution of claim 1, wherein the at least one pharmaceutically active ingredient is a toxin, virus, virus component, component of bacteriological cell walls, soluble messenger substance, dye, thrombolytic agent, tumor necrosis factor, nucleic acid, peptide, protein, glycoprotein, hormone, cytokine prostaglandin or combination thereof.
Claim 8
Dependent Claim
19 words
The microparticle solution of claim 1, wherein the at least one pharmaceutically active ingredient is cells and/or cell components.
Claim 9
Dependent Claim
39 words
The microparticle solution of claim 1, wherein the gaseous phase comprises air, nitrogen, oxygen, carbon dioxide, noble gases, ammonia, halogenated or partially halogenated hydrocarbon, SF 6 , steam, a liquid with a boiling point <37° C. or combinations thereof.
Claim 10
Dependent Claim
23 words
The microparticle solution of claim 1, wherein the pharmaceutically active ingredient is at least one nucleic acid, peptide, protein, glycoprotein, hormone or prostaglandin.
Claim 11
Independent Claim
126 words
A method for in-vivo release of an active ingredient which comprises: providing in-vivo a microparticle solution having microparticles comprising a shell of a biodegradable polymer which is a gelatin, fibrinogen collagen crosslinked polypeptide reaction producer of proteins with polyethylene glycol, starch, chitin, chitosan, pectin, polylactic acid, copolymer consisting of lactic acid and glycolic acid, polycyanoacrylate, polyester, polyamide, polycarbonate, polyphosphazene polyamino acid, poly-ξ-caprolactone, copolymer consisting of lactic acid and ξ-caprolactone or a mixture thereof; and incorporated therein a gaseous phase and at least one pharmaceutically active ingredient, the solution having no pharmaceutically active ingredient other than within the microparticles, and applying ultrasound waves to the microparticles such that the shell is destroyed and the at least one pharmaceutically active ingredient is released in-vivo only at this time.
Claim 12
Independent Claim
126 words
A method for in-vivo release of an active ingredient which comprises: providing in-vivo a microparticle solution having microparticles comprising a shell of a biodegradable polymer which is a gelatin, fibrinogen collagen crosslinked polypeptide reaction producer of proteins with polyethylene glycol, starch, chitin, chitosan, pectin, polylactic acid, copolymer consisting of lactic acid and glycolic acid, polycyanoacrylate, polyester, polyamide, polycarbonate, polyphosphazene polyamino acid, poly-ξ-caprolactone, copolymer consisting of lactic acid and ξ-caprolactone or a mixture thereof; and incorporated therein a gaseous phase and at least one pharmaceutically active ingredient, the solution having no pharmaceutically active ingredient other than within the microparticles, and applying ultrasound waves to the microparticles such that the shell is destroyed and the at least one pharmaceutically active ingredient is released in-vivo only at this time.
Claim 13
Dependent Claim
20 words
The method according to claim 10, wherein the density of the microparticle solution is less than 0.8 g/cm 3 .
Claim 14
Dependent Claim
18 words
The method according to claim 10, wherein the particle size of the microparticle solution is from 0.1-10 μm.
Claim 15
Dependent Claim
58 words
The method according to claim 10, wherein the biodegradable polymer is a protein, gelatin, fibrinogen, collagen, crosslinked polypeptide, reaction product of proteins with polyethylene glycol, starch, chitin, chitosan, pectin, polylactic acid, copolymer consisting of lactic acid and glycolic acid, polycyanoacrylate, polyester, polyamide, polycarbonate, polyphosphazene, polyamino acid, poly-ξ-caprolactone, copolymer consisting of lactic acid and ξ-caprolactone or a mixture thereof.
Claim 16
Dependent Claim
44 words
The method according to claim 10, wherein the at least one active ingredient is a toxin, virus, virus component, component of bacteriological cell walls, soluble messenger substance, dye, thrombolytic agent, tumor necrosis factor, nucleic acid, peptide, protein, glycoprotein, hormone, cytokine, prostaglandin or combination thereof.
Claim 17
Dependent Claim
18 words
The method according to claim 10, wherein the at least one active ingredient is cells and/or their components.
Claim 18
Dependent Claim
41 words
The method according to claim 10, wherein the gaseous phase is air, nitrogen, oxygen, carbon dioxide, a noble gas, ammonia, a halogenated or partially halogenated hydrocarbon, SF 6 , steam, a liquid having a boiling point <37° C. or mixtures thereof.
Claim 19
Dependent Claim
17 words
The method of claim 10, wherein the ultrasound waves are applied at a frequency of 1-6 MHZ.
Claim 20
Dependent Claim
17 words
The method of claim 10, wherein the ultrasound waves are applied at a frequency of 1.5-5 MHZ.
Claim 21
Dependent Claim
21 words
The method of claim 10, wherein the ultrasound waves are applied at a frequency below the resonance frequency of the microparticles.
Claim 22
Dependent Claim
57 words
Process for the production of microparticle solution containing a gaseous phase and at least one pharmaceutically active ingredient releasable in vivo by application of ultrasound waves which comprises treating in an autoclave microparticle solution comprising a gaseous phase in a biocompatible shell with a solution of the at least one pharmaceutically active ingredient in a supercritical gas.
Claim 23
Dependent Claim
57 words
Process for the production of microparticle solution containing a gaseous phase and at least one pharmaceutically active ingredient releasable in vivo by application of ultrasound waves which comprises treating in an autoclave microparticle solution comprising a gaseous phase in a biocompatible shell with a solution of the at least one pharmaceutically active ingredient in a supercritical gas.
Claim 24
Dependent Claim
24 words
The process of claim 19, wherein the supercritical gas is supercritical carbon dioxide, supercritical nitrogen, supercritical ammonia supercritical noble gas, or a combination thereof.
Claim 25
Dependent Claim
23 words
The process of claim 20, wherein the treated microparticle solution are subsequently washed to remove active ingredient not incorporated within the biocompatible shell.
Claim 26
Dependent Claim
13 words
The process of claim 20, wherein the treated microparticle solution are subsequently freeze-dried.
References Cited (Backward Citations)
US5190766A
Cited
EP0504881A2
Cited
US5529766A
Cited
US5529766C1
Cited
WO1992022298A1
Cited
WO1993000933A1
Cited
US5562893A
Cited
US5611344A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2003-05-30 | 2003-11-29 | 2004-05-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2007-05-30 | 2007-11-29 | 2008-05-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2011-05-30 | 2011-11-29 | 2012-05-30 | $7700.00 | Window Closed / Lapsed |